CD8A and melanoma: Involving 167 patients with resected stage IIB to IV melanoma, the trial revealed that melanoma-associated helper peptides paradoxically decreased CD8(+) T-cell responses, while CY pretreatment had no significant immunologic or clinical effect [155].